Belzutifan Demonstrates Significant Efficacy in Advanced Pheochromocytoma and Paraganglioma

A multicenter phase II clinical trial led by researchers at the University of Texas MD Anderson Cancer Center demonstrated significant tumor shrinkage and disease control in patients with advanced pheochromocytoma and paraganglioma (PPGL), two rare and possibly fatal neuroendocrine tumors.

The results of this study, led by Camilo Jimenez, MD, professor of endocrine neoplasia and hormonal disorders, were published today in the New England Journal of Medicine and presented simultaneously at the European Society for Medical oncology (ESMO) 2025 congress (abstract 1705O).

What was the main conclusion of the trial?

The trial demonstrated that belzutifan, a HIF-2α inhibitor, exhibited significant antitumor activity with an objective response rate of 61% and disease control rate of 83% in patients with advanced PPGL who had progressed despite prior therapies. This suggests belzutifan could be a new treatment option for this challenging cancer.

How does Belzutifan work?

Belzutifan targets HIF-2α, a protein that plays a crucial role in the development and progression of PPGL. By inhibiting HIF-2α, belzutifan can slow tumor growth and even cause tumors to shrink. PPGL tumors often have mutations that activate the HIF pathway, making them notably susceptible to this type of treatment.

Key Findings of the Trial

• Objective Response Rate: 61% of patients experienced tumor shrinkage.
• Disease Control Rate: 83% of patients had stable disease or tumor shrinkage.
• Duration of Response: Responses were durable, with a median duration of 12.1 months.
• Safety Profile: Belzutifan was generally well-tolerated, with the most common side effects being anemia, fatigue, and nausea.

Who was included in the study?

The study enrolled 60 patients with advanced PPGL that had progressed despite prior therapies,including surgery,radiation,and chemotherapy. Patients had a median of three prior lines of therapy. The study included patients with both sporadic and hereditary forms of PPGL.

What are the next steps?

based on these promising results, researchers are planning a Phase III clinical trial to confirm the efficacy and safety of belzutifan in a larger patient population. This larger trial will be crucial for seeking regulatory approval for belzutifan as a treatment for advanced PPGL. Further research will also focus on identifying biomarkers that can predict which patients are most likely to respond to belzutifan.

FAQ

Q: What are pheochromocytoma and paraganglioma?

A: These are rare neuroendocrine tumors that develop in the adrenal glands (pheochromocytoma) or other locations in the body (paraganglioma). they can cause a variety of symptoms, including high blood pressure, headaches, and sweating.

Q: What is HIF-2α?

A: HIF-2α is a protein that regulates the body’s response to low oxygen levels. It plays a key role in the development and progression of PPGL.

Q: Is belzutifan currently approved for the treatment of PPGL?

A: No, belzutifan is not yet approved for the treatment of PPGL. However,it is being investigated in clinical trials and shows significant promise.

Publication Date: 2025/10/19 03:22:32